^
    12d
    HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Seattle Children's Hospital | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    HER2-Specific CAR T
    1year
    HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting | N=48 --> 10
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    HER2-Specific CAR T